The Emergence of Diverse Drug-Resistance Mechanisms from Drug Tolerant Cancer Persister Cells
dc.contributor.advisor | Mendell, Joshua T. | en |
dc.contributor.committeeMember | Shay, Jerry W. | en |
dc.contributor.committeeMember | Cobb, Melanie H. | en |
dc.contributor.committeeMember | Altschuler, Steven J. | en |
dc.contributor.committeeMember | Wu, Lani | en |
dc.contributor.committeeMember | Wu, Jiang I. | en |
dc.creator | Ramirez, Michael Edward | en |
dc.creator.orcid | 0000-0002-8591-1641 | |
dc.date.accessioned | 2018-01-04T21:09:49Z | |
dc.date.available | 2018-01-04T21:09:49Z | |
dc.date.created | 2015-12 | |
dc.date.issued | 2015-08-31 | |
dc.date.submitted | December 2015 | |
dc.date.updated | 2018-01-04T21:03:43Z | |
dc.description.abstract | Cancer therapy has traditionally focused on eliminating fast-growing populations of cells, yet a growing body of evidence suggests that small subpopulations of cancer cells can evade strong selective drug pressure by entering a slow-growing "persister" state. This drug-tolerant state has been hypothesized to be part of an initial strategy towards eventual acquisition of bona fide drug-resistance mechanisms. However, the diversity and clinical relevance of drug-resistance mechanisms that can expand from a persister bottleneck is unknown. Here, we compared persister-derived, erlotinib-resistant colonies that arose from a single, EGFR-addicted lung cancer cell. We found, using a combination of large-scale drug screening and whole-exome sequencing, that our erlotinib-resistant colonies had acquired diverse resistance mechanisms, including the most commonly observed clinical resistance mechanisms. Thus, the drug-tolerant persister state does not limit--and may even provide a latent reservoir of cells--from which drug-resistance heterogeneity can emerge. | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.oclc | 1017760182 | |
dc.identifier.uri | https://hdl.handle.net/2152.5/4448 | |
dc.language.iso | en | en |
dc.subject | Antineoplastic Agents | en |
dc.subject | Drug Resistance, Neoplasm | en |
dc.subject | Erlotinib Hydrochloride | en |
dc.subject | Lung Neoplasms | en |
dc.title | The Emergence of Diverse Drug-Resistance Mechanisms from Drug Tolerant Cancer Persister Cells | en |
dc.type | Thesis | en |
dc.type.material | text | en |
thesis.degree.department | Graduate School of Biomedical Sciences | en |
thesis.degree.discipline | Cancer Biology | en |
thesis.degree.grantor | UT Southwestern Medical Center | en |
thesis.degree.level | Doctoral | en |
thesis.degree.name | Doctor of Philosophy | en |